Oryzon Genomics S A : announces FDA clearance of IND to initiate a collaborative Phase II basket study with iadademstat in R/R patients with Neuroendocrine carcinomas (NECs)

Press/Media

PeriodNov 9 2022

Media coverage

1

Media coverage